Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.
The diagnostics subsidiary, created by Oxford Nanopore Technologies last year, plans to forge partnerships with clinical and industry partners.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.
Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing
Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.